Dr Abou-Alfa Discusses POLO Trial, Olaparib to Treat gBRCA-mutated, Metastatic Pancreatic Cancer

from Oncology Learning Network · host HMP Global

Recapping a late-breaking abstract from ASCO 2019, Dr Abou-Alfa discusses POLO Trial, Olaparib to Treat gBRCA-mutated, Metastatic Pancreatic Cancer.Since the recording of this podcast, olaparib has been approved by the FDA as maintenance therapy for gBRCA-mutated metastatic pancreatic cancer as of December 30, 2019.

Episode metadata supplied by the publisher feed · Published Jan 3, 2020

Embed this episode

Attribution link and audio player

Ready to play

Dr Abou-Alfa Discusses POLO Trial, Olaparib to Treat gBRCA-mutated, Metastatic Pancreatic Cancer

0:00 2:49

1×

No transcript for this episode yet

We transcribe on demand. Request one and we'll notify you when it's ready — usually under 10 minutes.

Share this episode

Similar Episodes

No similar episodes found.

Similar Podcasts

No similar podcasts found.

Frequently Asked Questions

How long is this episode of Oncology Learning Network?

This episode is 2 minutes long.

When was this Oncology Learning Network episode published?

This episode was published on January 3, 2020.

Can I download this Oncology Learning Network episode?

Yes. Use the download control on the episode player to save the publisher-provided media file.

URL copied to clipboard!